US Bancorp DE Has $30.98 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• US Bancorp DE trimmed its stake in Edwards Lifesciences by 4.1% in Q4, selling 15,402 shares and ending the period with 363,376 shares valued at about $30.98 million (roughly 0.06% of the company).
• Edwards beat estimates on its most recent quarter with $0.78 EPS vs. $0.73 expected and $1.65 billion revenue vs. $1.60 billion, a 16.7% YoY revenue gain, and set FY2026 guidance of $2.95–3.05 EPS.
• Insiders sold 86,058 shares worth approximately $7.12 million over the past three months (including sales by the CFO and a VP), leaving insiders with just 0.31% ownership while institutions hold about 79.46%.

US Bancorp DE reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 363,376 shares of the medical research company's stock after selling 15,402 shares during the period. US Bancorp DE owned about 0.06% of Edwards Lifesciences worth $30,978,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Level Four Advisory Services LLC lifted its holdings in Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock valued at $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC lifted its holdings in Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after purchasing an additional 120 shares during the last quarter. Evermay Wealth Management LLC lifted its holdings in Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock valued at $282,000 after purchasing an additional 128 shares during the last quarter. Howard Capital Management Inc. lifted its holdings in Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock valued at $322,000 after purchasing an additional 132 shares during the last quarter. Finally, Florida Trust Wealth Management Co lifted its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company's stock valued at $751,000 after purchasing an additional 132 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.7%

Shares of NYSE EW opened at $84.08 on Friday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $87.89. The company has a market cap of $48.47 billion, a PE ratio of 44.72, a P/E/G ratio of 2.10 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $82.08 and a two-hundred day moving average of $82.41.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm posted $0.64 earnings per share. The company's revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an "outperform" rating in a report on Monday, April 13th. Barclays reissued an "overweight" rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday. The Goldman Sachs Group reissued a "buy" rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a "buy" rating in a report on Tuesday, January 20th. Finally, Piper Sandler reissued an "overweight" rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $95.65.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares of the company's stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 86,058 shares of company stock valued at $7,118,636. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.